# MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

> **NCT06171685** · PHASE2 · RECRUITING · sponsor: **Multiple Myeloma Research Consortium** · enrollment: 300 (estimated)

## Conditions studied

- Relapse Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Teclistamab Monotherapy
- **DRUG:** Teclistamab

## Key facts

- **NCT ID:** NCT06171685
- **Lead sponsor:** Multiple Myeloma Research Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-17
- **Primary completion:** 2029-07-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06171685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06171685, "MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06171685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*